Celldex Acquires Exclusive Rights to Immune-stimulatory Molecules from Amgen
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Celldex Therapeutics, Inc. has announced that the Company has expanded its Precision Targeted Immunotherapy Platform by acquiring exclusive rights to FMS-like tyrosine kinase 3 ligand (Flt3L) and CD40 ligand (CD40L), from Amgen.
Specific terms of the agreement were not disclosed. Flt3L and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex believes these ligands may hold significant opportunity for synergistic development in combination with other proprietary molecules in the Company’s portfolio.
“We are extremely pleased to be in the position to continue the clinical development of these biologically active molecules,” said Tibor Keler, Chief Scientific Officer of Celldex Therapeutics. “In particular, we believe that Flt3L has significant potential to be developed in a number of indications in cancer, inflammatory and infectious diseases.
“This agreement with Amgen is part of Celldex’s ongoing development strategy to identify technology and product candidates that we believe hold significant value that can be unlocked with our Precision Targeted Immunotherapy Platform,” added Anthony Marucci, President and CEO of Celldex Therapeutics.
Specific terms of the agreement were not disclosed. Flt3L and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex believes these ligands may hold significant opportunity for synergistic development in combination with other proprietary molecules in the Company’s portfolio.
“We are extremely pleased to be in the position to continue the clinical development of these biologically active molecules,” said Tibor Keler, Chief Scientific Officer of Celldex Therapeutics. “In particular, we believe that Flt3L has significant potential to be developed in a number of indications in cancer, inflammatory and infectious diseases.
“This agreement with Amgen is part of Celldex’s ongoing development strategy to identify technology and product candidates that we believe hold significant value that can be unlocked with our Precision Targeted Immunotherapy Platform,” added Anthony Marucci, President and CEO of Celldex Therapeutics.
